REDX.L
Redx Pharma Plc [REDX.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
REDX.L Stock Summary
Top 10 Correlated ETFs
REDX.L
Top 10 Correlated Stocks
REDX.L
In the News
REDX.L Financial details
Company Rating
Neutral
Market Cap
28.88M
Income
-51.16M
Revenue
22.89M
Book val./share
0.01
Cash/share
0.05
Dividend
-
Dividend %
-
Employees
101
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
0
Forward P/E
-
PEG
-
P/S
20.37
P/B
-
P/C
255
P/FCF
-2.45
Quick Ratio
0.86
Current Ratio
1.11
Debt / Equity
5.27
LT Debt / Equity
0.38
-
-
EPS (TTM)
-0.16
EPS next Y
-
EPS next Q
-
EPS this Y
61.76%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
23.76%
Revenue last 5Y
6.06%
Revenue Q/Q
-18.17%
EPS Q/Q
-40.32%
-
-
-
-
SMA20
-56.2%
SMA50
-56.62%
SMA100
-65.39%
Inst Own
-
Inst Trans
-
ROA
-129%
ROE
-181%
ROC
-7.31%
Gross Margin
100%
Oper. Margin
-805%
Profit Margin
-789%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.0-37.9
52W High
-65.54%
52W Low
+218.75%
RSI
49.35
Rel Volume
1.09
Avg Volume
767K
Volume
839.83K
Perf Week
121.74%
Perf Month
-27.14%
Perf Quarter
-50.96%
Perf Half Y
-50.96%
-
-
-
-
Beta
-0.533
-
-
Volatility
2.43%, 6.09%
Prev Close
-5.56%
Price
12.75
Change
19.16%
REDX.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-09-30
| Metric | History | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.03 | 0.04 | 0.06 | 0.01 | |
| Net income per share | -0.03 | -0.05 | -0.08 | -0.06 | -0.1 | |
| Operating cash flow per share | -0.04 | 0 | -0.08 | -0.03 | -0.1 | |
| Free cash flow per share | -0.04 | 0 | -0.09 | -0.03 | -0.1 | |
| Cash per share | 0.03 | 0.16 | 0.15 | 0.18 | 0.05 | |
| Book value per share | 0.01 | 0.02 | 0.05 | 0.11 | 0.01 | |
| Tangible book value per share | 0.01 | 0.01 | 0.05 | 0.11 | 0.01 | |
| Share holders equity per share | 0.01 | 0.02 | 0.05 | 0.11 | 0.01 | |
| Interest debt per share | 0 | 0.13 | 0.07 | 0.07 | 0.06 | |
| Market cap | 10.12M | 96.08M | 219.25M | 166.21M | 87.08M | |
| Enterprise value | 6.89M | 89.03M | 207.09M | 130.66M | 86.67M | |
| P/E ratio | -2.34 | -10.43 | -10.16 | -9.23 | -2.63 | |
| Price to sales ratio | 3.23 | 16.9 | 21.85 | 8.89 | 20.72 | |
| POCF ratio | -2.17 | 243.23 | -10.26 | -19.62 | -2.51 | |
| PFCF ratio | -2.16 | 285.94 | -9.91 | -19.03 | -2.49 | |
| P/B Ratio | 6.79 | 35.76 | 16.7 | 4.99 | 25.95 | |
| PTB ratio | 6.79 | 35.76 | 16.7 | 4.99 | 25.95 | |
| EV to sales | 2.2 | 15.66 | 20.64 | 6.99 | 20.62 | |
| Enterprise value over EBITDA | -0.97 | -11.71 | -10.84 | -8.6 | -2.96 | |
| EV to operating cash flow | -1.47 | 225.4 | -9.69 | -15.43 | -2.49 | |
| EV to free cash flow | -1.47 | 264.98 | -9.36 | -14.96 | -2.48 | |
| Earnings yield | -0.43 | -0.1 | -0.1 | -0.11 | -0.38 | |
| Free cash flow yield | -0.46 | 0 | -0.1 | -0.05 | -0.4 | |
| Debt to equity | 0.31 | 7.62 | 1.32 | 0.55 | 5.27 | |
| Debt to assets | 0.07 | 0.61 | 0.44 | 0.29 | 0.69 | |
| Net debt to EBITDA | 0.46 | 0.93 | 0.64 | 2.34 | 0.01 | |
| Current ratio | 1.19 | 2.7 | 3.73 | 2.18 | 1.11 | |
| Interest coverage | -70.52 | -8.49 | -11.54 | -9.43 | -18.78 | |
| Income quality | 1.08 | -0.04 | 0.99 | 0.47 | 1.05 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.02 | 0.01 | 0.64 | 0.55 | 1.92 | |
| Research and developement to revenue | 1.97 | 1.75 | 2.44 | 1.53 | 6.93 | |
| Intangibles to total assets | 0.07 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Capex to operating cash flow | 0.01 | -0.15 | 0.04 | 0.03 | 0.01 | |
| Capex to revenue | -0.01 | -0.01 | -0.08 | -0.01 | -0.05 | |
| Capex to depreciation | -0.31 | -0.09 | -1.19 | -0.3 | -0.2 | |
| Stock based compensation to revenue | 0.01 | 0.1 | 0.38 | 0.23 | 0.76 | |
| Graham number | 0.1 | 0.14 | 0.31 | 0.39 | 0.15 | |
| ROIC | -2.5 | -0.31 | -0.59 | -0.3 | -1.49 | |
| Return on tangible assets | -0.73 | -0.28 | -0.55 | -0.29 | -1.31 | |
| Graham Net | 0 | -0.01 | 0.06 | 0.09 | -0.01 | |
| Working capital | 940K | 18.53M | 26.22M | 32.17M | 2.3M | |
| Tangible asset value | 1.07M | 2.28M | 12.73M | 32.92M | 2.96M | |
| Net current asset value | 940K | -1.43M | 9.4M | 30.22M | 1.02M | |
| Invested capital | 0.31 | 7.62 | 1.32 | 0.55 | 5.27 | |
| Average receivables | 1.81M | 1.69M | 4.11M | 5.89M | 3.08M | |
| Average payables | 3.62M | 3.4M | 4.03M | 5.33M | 4.86M | |
| Average inventory | -1.09M | 0 | 0 | -2.76M | -2.76M | |
| Days sales outstanding | 166.24 | 125.52 | 227.8 | 107.88 | 54.9 | |
| Days payables outstanding | 3.59K | 0 | 0 | 0 | 1.43K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 2.2 | 2.91 | 1.6 | 3.38 | 6.65 | |
| Payables turnover | 0.1 | 0 | 0 | 0 | 0.26 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -2.9 | -3.43 | -1.64 | -0.54 | -9.88 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q4
| Metric | History | 2021-09-30 | 2022-03-31 | 2022-09-30 | 2023-03-31 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.03 | 0.03 | 0.03 | 0.01 | 0.01 | |
| Net income per share | -0.03 | -0.04 | -0.03 | -0.06 | -0.04 | |
| Operating cash flow per share | -0.04 | 0.01 | -0.03 | -0.06 | -0.05 | |
| Free cash flow per share | -0.04 | 0.01 | -0.03 | -0.06 | -0.05 | |
| Cash per share | 0.14 | 0.11 | 0.17 | 0.1 | 0.05 | |
| Book value per share | 0.05 | 0.02 | 0.1 | 0.04 | 0.01 | |
| Tangible book value per share | 0.05 | 0.02 | 0.1 | 0.04 | 0.01 | |
| Share holders equity per share | 0.05 | 0.02 | 0.1 | 0.04 | 0.01 | |
| Interest debt per share | 0.07 | 0.07 | 0.06 | 0.06 | 0.06 | |
| Market cap | 235.37M | 205.09M | 180.93M | 103.82M | 87.08M | |
| Enterprise value | 223.21M | 191.34M | 145.38M | 88.01M | 86.67M | |
| P/E ratio | -6.64 | -5.25 | -5.49 | -1.25 | -1.76 | |
| Price to sales ratio | 29.67 | 24.55 | 17.5 | 44.93 | 46.05 | |
| POCF ratio | -23.45 | 79.21 | -16.36 | -5.56 | -5.42 | |
| PFCF ratio | -22.94 | 84.36 | -16.21 | -5.51 | -5.4 | |
| P/B Ratio | 17.92 | 38.12 | 5.43 | 6.96 | 25.95 | |
| PTB ratio | 17.92 | 38.12 | 5.43 | 6.96 | 25.95 | |
| EV to sales | 28.13 | 22.91 | 14.06 | 38.08 | 45.83 | |
| Enterprise value over EBITDA | -28.52 | -22.77 | -15.67 | -4.88 | -6.2 | |
| EV to operating cash flow | -22.23 | 73.91 | -13.15 | -4.71 | -5.39 | |
| EV to free cash flow | -21.76 | 78.71 | -13.02 | -4.67 | -5.38 | |
| Earnings yield | -0.04 | -0.05 | -0.05 | -0.2 | -0.14 | |
| Free cash flow yield | -0.04 | 0.01 | -0.06 | -0.18 | -0.19 | |
| Debt to equity | 1.32 | 3.32 | 0.55 | 1.26 | 5.27 | |
| Debt to assets | 0.44 | 0.45 | 0.29 | 0.44 | 0.69 | |
| Net debt to EBITDA | 1.55 | 1.64 | 3.83 | 0.88 | 0.03 | |
| Current ratio | 3.73 | 2.11 | 2.18 | 1.52 | 1.11 | |
| Interest coverage | -11.37 | -10.4 | -11.11 | -20.66 | -15.99 | |
| Income quality | 1.13 | -0.27 | 1.34 | 0.9 | 1.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 1.55 | 1.51 | 6.97 | 6.89 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Capex to operating cash flow | 0.02 | -0.06 | 0.01 | 0.01 | 0 | |
| Capex to revenue | -0.03 | -0.02 | -0.01 | -0.07 | -0.02 | |
| Capex to depreciation | -0.86 | -0.36 | -0.23 | -0.33 | -0.07 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.19 | 0.12 | 0.25 | 0.25 | 0.09 | |
| ROIC | -0.24 | -0.34 | -0.18 | -0.52 | -0.64 | |
| Return on tangible assets | -0.23 | -0.25 | -0.13 | -0.49 | -0.49 | |
| Graham Net | 0.05 | -0.01 | 0.08 | 0.03 | -0.01 | |
| Working capital | 26.22M | 19.17M | 32.17M | 13.78M | 2.3M | |
| Tangible asset value | 12.73M | 4.98M | 32.92M | 14.53M | 2.96M | |
| Net current asset value | 9.4M | 1.93M | 30.22M | 12.16M | 1.02M | |
| Invested capital | 1.32 | 3.32 | 0.55 | 1.26 | 5.27 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 71.04 | 52.87 | 48.1 | 213.06 | 30.08 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 728.53 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1.27 | 1.7 | 1.87 | 0.42 | 2.99 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0.12 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.67 | -1.81 | -0.25 | -1.39 | -3.69 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
REDX.L Frequently Asked Questions
What is Redx Pharma Plc stock symbol ?
Redx Pharma Plc is a GB stock and trading under the symbol REDX.L
What is Redx Pharma Plc stock quote today ?
Redx Pharma Plc stock price is $12.75 today.
Is Redx Pharma Plc stock public?
Yes, Redx Pharma Plc is a publicly traded company.
Company Profile
- Volume Average 767K
- Market Capitalization 28.88M
- Employee 101
- CEO Ms. Lisa Mary Whewell Anson
- Headquarters Macclesfield,GB
- IPO Date 2015-03-27
-
Website
https://www.redxpharma.com 
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
